Mundipharma helps fight common colds with introduction of BETADINE® Cold Defence

February 22, 2017 - 5 minutes read
  • A natural product with anti-viral effects further extends the BETADINE® product range
  • A new treatment that helps to eliminate 99% of cold and flu viruses and shorten the duration of common colds
  • First time to market in Asia in formulations for adults and children

Singapore, 22 February 2017: Mundipharma, the makers of the BETADINE® range of products, has introduced a new early treatment to help families stay healthy and better compete in the perennial fight against common cold.

_D2C3854

Common cold and flu-like illnesses are viral infections that affects adults twice per year on average. The impact is greater for children who can typically contract them up to five to seven times per year due to their close proximity at school and play.

Clinical trials have shown the treatment reduced duration of disease by up to two days, increased viral clearance and reduced severity of cold and flu-like symptoms in children and adults.

Professor Ronald Eccles, who established the Common Cold Centre at Cardiff University in 1988 and has been involved in over 120 clinical trials for over 30 years, said “This is an exciting development in the fight against the common cold.”

BETADINE® Cold Defence is a natural product with anti-viral effects that helps reduce duration of colds in adults and children. It is delivered as a nasal spray and contains the ingredient iota-carrageenan, also called Carragelose®. It is available in adult and children’s formulations and is recommended for use at the first sign of cold and flu-like symptoms.

Several large scale clinical trials involving close to 600 adult and pediatric patients were conducted to evaluate the efficacy and safety of the nasal spray. The analysis of children and adults suffering from virus-confirmed common cold after two randomized, double-blind, placebo-controlled trials the nasal spray appeared as an effective treatment of common cold.1

Raman Singh, President Mundipharma Asia Pacific, Latin America, Middle East and Africa, said “Every year the common cold interrupts family, school and working life, soaking up medical leave, putting pressure on productivity and colleagues and interrupting people’s daily life. As an early treatment to manage the Cold and other flu-like illnesses, BETADINE® Cold Defence can help keep families and workplaces productive and healthy.”

“The addition of BETADINE® Cold Defence to our BETADINE® range continues our commitment to the day-to-day wellbeing of families.”

Ends

About Mundipharma

Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

For more information please visit: www.mundipharma.com.sg

About BETADINE®

The BETADINE® range of products is trusted by hospitals around the world for over 60 years to prevent and treat infections. A trusted brand among consumers at home to treat small wounds and grazes, sore throats, feminine infections and to stop minor problems from escalating into big issues. In-vitro studies show that BETADINE® medicines containing Povidone-Iodine kill a broad range of bacteria, viruses and fungi including antibiotic-resistant strains that cause infections. BETADINE® has four main categories of products in Wound Care, Feminine Care, Throat / Oral Care and Infectious Diseases to meet the varying needs of our customers.

® : BETADINE is a registered trademark of Mundipharma

® : Carregelose is a Registered Trademark of Marinomed.

Registered indications differ country to country hence please check with a local Mundipharma office for more information on the local approved prescribing information.

For further information please contact:

Stephenie Vasko

Chief Communications Officer & Head, Digital Strategy –

Asia Pacific, Latin America the Middle East & Africa

+65-6303-9732 | stephenie.vasko@mundipharma.com.sg

[1] ‘Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold’, Tamas Fazekas, Philipp Eickhoff, Nathalie Pruckner, Georg Vollnhofer, Gustav Fischmeister, Christopher Diakos, Margit Rauch, Maria Verdianz, Andreas Zoubek, Helmut Gadner and Thomas Lion, BMC Complementary and Alternative Medicine, The official journal of the International Society for Complementary Medicine. Published, 5 September 2012.